raltegravir-mk-0518

Description: Raltegravir (formerly also known as MK-0518; trade name: Isentress) is a novel, potent integrase (IN) inhibitor for WT and S217Q PFV IN with IC50 of 90 nM and 40 nM in cell-free assays, respectively. Raltegravir is an antiretroviral drug used to treat HIV infection. Raltegravir binds to and inhibits integrase, an HIV enzyme that inserts viral genetic material into the genetic material of the infected human cell. Inhibition of integrase prevents insertion of HIV DNA into the human DNA genome, thus blocking HIV replication. It is the first integrase inhibitors that received FDA approval for HIV treatment.

References: Proc Natl Acad Sci U S A. 2010 Nov 16; 107(46):20057-62; Retrovirology. 2010; 7:21.

Related CAS#: 871038-72-1 (potassium salt)